Merck has characterized its cost-cutting initiative as more of a reallocation of resources to support other, higher-growth ...

Merck will reduce its workforce by approximately 6,000 employees in “some areas of our global workforce,” the New Jersey ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

The European Commission (EC) has granted conditional approval to SpringWorks Therapeutics’ Ezmekly (mirdametinib) to treat ...

The European Commission granted conditional marketing authorization for Ezmekly (mirdametinib) for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in pediatric and adult patients ...

STAMFORD, Conn., July 18, 2025 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted ...

EZMEKLY is the first and only therapy to receive marketing authorization in the EU for both adults and children (≥2 years) with NF1-PN, a rare genetic disorder with debilitating symptoms –STAMFORD, ...

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany, announced today that the European Commission (EC) granted conditional marketing authorization ...

Merck KGaA is still scouting for acquisition targets after the German drug-to-semiconductor group completed its $3.9 billion takeover of SpringWorks Therapeutics Inc. on Tuesday.